Literature DB >> 19951008

Heparin for patients with growth restricted fetus: a prospective randomized controlled trial.

Yan-Hong Yu1, Li-Yong Shen, Hua Zou, Zhi-Jian Wang, Shi-Peng Gong.   

Abstract

OBJECTIVE: Heparin was hypothesized to facilitate the growth of the growth-restricted fetus. Our study was to assess the efficiency of heparin in treating fetus with growth restriction and to explore the possible mechanisms.
METHODS: Seventy-three pregnant women were selected in this study. Based on regular treatments, patients randomly received either heparin or dan-shen combined with low-molecular weight dextrose. A serial ultrasonography and hematological measurements were performed on each patient at the enrolment and 7 days after the first treatment. Neonatal birth weight, 1-min Apgar score and gestational age were recorded. Placentas were collected for apoptotic indices.
RESULTS: Heparin significantly improved maternal hemorrheological indices, fetal growth velocities and neonatal outcomes. It also reduced apoptosis in trophoblasts.
CONCLUSIONS: Our results provide evidence that heparin significantly improves the growth of the growth-restricted fetus. The growth improvement is probably achieved by the changes in maternal hemorrheology and the attenuated apoptosis in trophoblasts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19951008     DOI: 10.3109/14767050903443459

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  2 in total

1.  Maternal low molecular weight heparin versus sildenafil citrate for fetal growth restriction: a randomized, parallel groups, open-label clinical trial.

Authors:  R Rasheedy; G El Bishry; R Tarek
Journal:  J Perinatol       Date:  2019-11-06       Impact factor: 2.521

2.  Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP).

Authors:  Edurne Mazarico; Anna Peguero; Marta Camprubí; Carlota Rovira; Maria Dolores Gomez Roig; Daniel Oros; Patricia Ibáñez-Burillo; Jon Schoorlemmer; Narcís Masoller; Maria Dolors Tàssies; Francesc Figueras
Journal:  BMJ Open       Date:  2018-10-23       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.